Dipna Pharmachem Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: November 17, 2025, 11:54 pm

Market Cap	43.2 Cr.
Current Price	18.0
High / Low	26.3/6.54
Stock P/E	44.6
Book Value	16.0
Dividend Yield	0.00 %
ROCE	6.64 %
ROE	2.55 %
Face Value	10.0
PEG Ratio	-1.62

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Dipna Pharmachem Ltd

Competitors of Dipna Pharmachem Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	159 Cr.	126	247/84.3	35.2	49.6	0.00 %	12.9 %	9.69 %	10.0
MPS Pharmaa Ltd	3.52 Cr.	1.84	4.33/1.82		0.33	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	4,872 Cr.	447	479/192	101	24.3	0.15 %	27.3 %	21.7 %	1.00
Gujarat Terce Laboratories Ltd	32.9 Cr.	44.3	92.2/37.2		10.6	0.00 %	41.4 %	14.6 %	10.0
Gujarat Inject (Kerala) Ltd	38.6 Cr.	26.4	29.1/17.0	91.9	6.93	0.00 %	13.5 %	11.0 %	10.0
Industry Average	20,386.93 Cr	1,192.94		53.65	202.19	0.34%	16.24%	14.95%	6.10

All Competitor Stocks of Dipna Pharmachem Ltd

Quarterly Result

Metric	Sep 2021	Mar 2022	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025
Sales	29	44	49	74	74	90	91	34
Expenses	28	42	48	73	73	88	89	32
Operating Profit	1	1	1	2	2	2	1	2
OPM %	3%	3%	2%	2%	2%	2%	2%	6%
Other Income	0	0	0	0	0	0	0	0
Interest	0	0	0	1	1	1	1	1
Depreciation	0	0	0	0	0	0	0	0
Profit before tax	0	1	0	1	1	1	0	1
Tax %	25%	26%	26%	27%	27%	21%	26%	34%
Net Profit	0	1	0	1	1	0	0	1
EPS in Rs	33.00	84.00	0.13	0.24	0.24	0.20	0.14	0.27

Last Updated: July 16, 2025, 10:10 am

Below is a detailed analysis of the quarterly data for Dipna Pharmachem Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 34.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Sep 2024) to 34.00 Cr., marking a decrease of 57.00 Cr..
For Expenses, as of Mar 2025, the value is 32.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 89.00 Cr. (Sep 2024) to 32.00 Cr., marking a decrease of 57.00 Cr..
For Operating Profit, as of Mar 2025, the value is 2.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Sep 2024) to 2.00 Cr., marking an increase of 1.00 Cr..
For OPM %, as of Mar 2025, the value is 6.00%. The value appears strong and on an upward trend. It has increased from 2.00% (Sep 2024) to 6.00%, marking an increase of 4.00%.
For Other Income, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
For Interest, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 1.00 Cr..
For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 0.00 Cr..
For Profit before tax, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
For Tax %, as of Mar 2025, the value is 34.00%. The value appears to be increasing, which may not be favorable. It has increased from 26.00% (Sep 2024) to 34.00%, marking an increase of 8.00%.
For Net Profit, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Sep 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 0.27. The value appears strong and on an upward trend. It has increased from 0.14 (Sep 2024) to 0.27, marking an increase of 0.13.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 3:29 am

Metric	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	17	20	30	31	73	100	164	125
Expenses	16	20	30	31	71	98	161	121
Operating Profit	0	0	0	0	2	2	3	4
OPM %	2%	2%	1%	1%	3%	2%	2%	3%
Other Income	0	0	0	0	0	0	0	0
Interest	0	0	0	0	1	1	2	2
Depreciation	0	0	0	0	0	0	0	0
Profit before tax	0	0	0	0	2	1	1	1
Tax %	14%	40%	0%	60%	26%	34%	24%	32%
Net Profit	0	0	0	0	1	1	1	1
EPS in Rs	6.00	3.00	6.00	2.00	117.00	0.37	0.45	0.40
Dividend Payout %	0%	0%	0%	0%	0%	0%	0%	0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	0.00%	0.00%	0.00%
Change in YoY Net Profit Growth (%)	0.00%	0.00%	0.00%

Dipna Pharmachem Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 3 years from 2022-2023 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	33%
3 Years:	20%
TTM:	-24%

Compounded Profit Growth
10 Years:	%
5 Years:	74%
3 Years:	-6%
TTM:	-11%

Stock Price CAGR
10 Years:	%
5 Years:	%
3 Years:	%
1 Year:	142%

Return on Equity
10 Years:	%
5 Years:	5%
3 Years:	4%
Last Year:	3%

Last Updated: September 5, 2025, 3:16 pm

No data available for the Balance Sheet data table.

Reserves and Borrowings Chart

Cash Flow - No data available for this post.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days	132	160	134	176	135	104	69	135
Inventory Days	112	66	70	89	34	72	86	88
Days Payable	142	148	105	145	123	139	172	243
Cash Conversion Cycle	103	78	99	120	46	38	-17	-20
Working Capital Days	3	6	44	47	37	108	80	137
ROCE %		8%	5%	3%	17%	9%	7%	7%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Sep 2022	Mar 2023	Sep 2023	Mar 2024	Sep 2024	Mar 2025	Sep 2025
Promoters	66.56%	66.56%	57.19%	9.98%	9.98%	9.98%	9.98%
Public	33.45%	33.43%	42.81%	90.02%	90.02%	90.01%	90.02%
No. of Shareholders	1,110	992	1,078	1,807	2,652	1,997	1,742

Shareholding Pattern Chart

No. of Shareholders

Dipna Pharmachem Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	0.41	0.45	260.55	333.40	6.91
Diluted EPS (Rs.)	0.41	0.45	260.55	333.40	6.91
Cash EPS (Rs.)	0.40	0.45	0.77	335.17	8.97
Book Value[Excl.RevalReserv]/Share (Rs.)	16.01	15.60	20.35	496.74	163.34
Book Value[Incl.RevalReserv]/Share (Rs.)	16.01	15.60	20.35	496.74	163.34
Revenue From Operations / Share (Rs.)	51.95	68.34	83.48	20787.26	8857.11
PBDIT / Share (Rs.)	1.43	1.43	1.96	644.23	118.66
PBIT / Share (Rs.)	1.43	1.42	1.95	642.46	116.60
PBT / Share (Rs.)	0.59	0.59	1.15	449.80	15.71
Net Profit / Share (Rs.)	0.40	0.45	0.76	333.40	6.91
PBDIT Margin (%)	2.75	2.08	2.35	3.09	1.33
PBIT Margin (%)	2.75	2.07	2.33	3.09	1.31
PBT Margin (%)	1.13	0.86	1.38	2.16	0.17
Net Profit Margin (%)	0.77	0.66	0.91	1.60	0.07
Return on Networth / Equity (%)	2.53	2.89	3.74	67.11	4.23
Return on Capital Employeed (%)	7.25	6.82	6.06	44.39	9.58
Return On Assets (%)	0.73	0.81	1.17	3.22	0.09
Long Term Debt / Equity (X)	0.23	0.33	0.58	1.91	6.44
Total Debt / Equity (X)	0.44	0.51	0.65	5.86	21.74
Asset Turnover Ratio (%)	0.94	1.56	1.76	2.38	1.43
Current Ratio (X)	1.56	1.60	1.99	1.16	1.21
Quick Ratio (X)	1.23	1.15	1.50	0.95	0.85
Inventory Turnover Ratio (X)	3.85	5.84	0.00	10.03	4.90
Interest Coverage Ratio (X)	1.71	1.72	2.46	3.34	1.18
Interest Coverage Ratio (Post Tax) (X)	1.48	1.54	1.95	2.73	1.07
Enterprise Value (Cr.)	51.18	28.22	25.24	0.00	0.00
EV / Net Operating Revenue (X)	0.40	0.17	0.25	0.00	0.00
EV / EBITDA (X)	14.85	8.22	10.74	0.00	0.00
MarketCap / Net Operating Revenue (X)	0.27	0.13	0.15	0.00	0.00
Price / BV (X)	0.89	0.60	0.61	0.00	0.00
Price / Net Operating Revenue (X)	0.27	0.13	0.15	0.00	0.00
EarningsYield	0.02	0.04	0.06	0.00	0.00

After reviewing the key financial ratios for Dipna Pharmachem Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
For Diluted EPS (Rs.), as of Mar 25, the value is 0.41. This value is below the healthy minimum of 5. It has decreased from 0.45 (Mar 24) to 0.41, marking a decrease of 0.04.
For Cash EPS (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 3. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 16.01. It has increased from 15.60 (Mar 24) to 16.01, marking an increase of 0.41.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 51.95. It has decreased from 68.34 (Mar 24) to 51.95, marking a decrease of 16.39.
For PBDIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is below the healthy minimum of 2. There is no change compared to the previous period (Mar 24) which recorded 1.43.
For PBIT / Share (Rs.), as of Mar 25, the value is 1.43. This value is within the healthy range. It has increased from 1.42 (Mar 24) to 1.43, marking an increase of 0.01.
For PBT / Share (Rs.), as of Mar 25, the value is 0.59. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.59.
For Net Profit / Share (Rs.), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 2. It has decreased from 0.45 (Mar 24) to 0.40, marking a decrease of 0.05.
For PBDIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.08 (Mar 24) to 2.75, marking an increase of 0.67.
For PBIT Margin (%), as of Mar 25, the value is 2.75. This value is below the healthy minimum of 10. It has increased from 2.07 (Mar 24) to 2.75, marking an increase of 0.68.
For PBT Margin (%), as of Mar 25, the value is 1.13. This value is below the healthy minimum of 10. It has increased from 0.86 (Mar 24) to 1.13, marking an increase of 0.27.
For Net Profit Margin (%), as of Mar 25, the value is 0.77. This value is below the healthy minimum of 5. It has increased from 0.66 (Mar 24) to 0.77, marking an increase of 0.11.
For Return on Networth / Equity (%), as of Mar 25, the value is 2.53. This value is below the healthy minimum of 15. It has decreased from 2.89 (Mar 24) to 2.53, marking a decrease of 0.36.
For Return on Capital Employeed (%), as of Mar 25, the value is 7.25. This value is below the healthy minimum of 10. It has increased from 6.82 (Mar 24) to 7.25, marking an increase of 0.43.
For Return On Assets (%), as of Mar 25, the value is 0.73. This value is below the healthy minimum of 5. It has decreased from 0.81 (Mar 24) to 0.73, marking a decrease of 0.08.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.23. This value is within the healthy range. It has decreased from 0.33 (Mar 24) to 0.23, marking a decrease of 0.10.
For Total Debt / Equity (X), as of Mar 25, the value is 0.44. This value is within the healthy range. It has decreased from 0.51 (Mar 24) to 0.44, marking a decrease of 0.07.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.94. It has decreased from 1.56 (Mar 24) to 0.94, marking a decrease of 0.62.
For Current Ratio (X), as of Mar 25, the value is 1.56. This value is within the healthy range. It has decreased from 1.60 (Mar 24) to 1.56, marking a decrease of 0.04.
For Quick Ratio (X), as of Mar 25, the value is 1.23. This value is within the healthy range. It has increased from 1.15 (Mar 24) to 1.23, marking an increase of 0.08.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.85. This value is below the healthy minimum of 4. It has decreased from 5.84 (Mar 24) to 3.85, marking a decrease of 1.99.
For Interest Coverage Ratio (X), as of Mar 25, the value is 1.71. This value is below the healthy minimum of 3. It has decreased from 1.72 (Mar 24) to 1.71, marking a decrease of 0.01.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.48. This value is below the healthy minimum of 3. It has decreased from 1.54 (Mar 24) to 1.48, marking a decrease of 0.06.
For Enterprise Value (Cr.), as of Mar 25, the value is 51.18. It has increased from 28.22 (Mar 24) to 51.18, marking an increase of 22.96.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.40. This value is below the healthy minimum of 1. It has increased from 0.17 (Mar 24) to 0.40, marking an increase of 0.23.
For EV / EBITDA (X), as of Mar 25, the value is 14.85. This value is within the healthy range. It has increased from 8.22 (Mar 24) to 14.85, marking an increase of 6.63.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
For Price / BV (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has increased from 0.60 (Mar 24) to 0.89, marking an increase of 0.29.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.27. This value is below the healthy minimum of 1. It has increased from 0.13 (Mar 24) to 0.27, marking an increase of 0.14.
For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 24) to 0.02, marking a decrease of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Dipna Pharmachem Ltd as of November 18, 2025 is: 14.85

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of November 18, 2025, Dipna Pharmachem Ltd is Overvalued by 17.50% compared to the current share price 18.00

Intrinsic Value of Dipna Pharmachem Ltd as of November 18, 2025 is: 10.76

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of November 18, 2025, Dipna Pharmachem Ltd is Overvalued by 40.22% compared to the current share price 18.00

Last 5 Year EPS CAGR: -27.52%

*Investments are subject to market risks

Strength and Weakness

Unable to fetch valid data for stock valuation.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dipna Pharmachem Ltd:
1. Net Profit Margin: 0.77%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 7.25% (Industry Average ROCE: 16.24%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 2.53% (Industry Average ROE: 14.95%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 1.48
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.23
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 44.6 (Industry average Stock P/E: 53.65)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.44
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Dipna Pharmachem Ltd. is a Public Limited Listed company incorporated on 19/07/2011 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24100GJ2011PLC066400 and registration number is 066400. Currently company belongs to the Industry of Pharmaceuticals. Company's Total Operating Revenue is Rs. 124.92 Cr. and Equity Capital is Rs. 24.05 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	A/211, Siddhi Vinayak Complex, Ahmedabad Gujarat 380055	info@dipnapharmachem.com http://www.dipnapharmachem.com

Management
Name	Position Held
Mr. Keyur Dipakkumar Shah	Managing Director
Ms. Dipna Keyur Shah	Non Executive Director
Mr. Nirav Soni	Non Executive Director
Mr. Nandish Shaileshbhai Jani	Independent Director
Mr. Parin Bhavsar	Independent Director

FAQ: Stock data is invalid or not in the correct format.